GIV/Girdin activates Gαi and inhibits Gαs via the same motif
- Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5721-30. doi: 10.1073/pnas.1609502113.
- 1. Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093;
- 2. Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118;
- 3. Department of Medicine, University of California, San Diego, La Jolla, CA 92093;
- 4. Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093; Department of Medicine, University of California, San Diego, La Jolla, CA 92093;
- 5. Department of Chemistry and Molecular Pharmacology, Institute for Research in Biomedicine, 08028 Barcelona, Spain;
- 6. Department of Psychiatry, University of California, San Francisco, CA 94158.
- 7. Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093; [email protected] [email protected].
- 8. Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093; Department of Medicine, University of California, San Diego, La Jolla, CA 92093; [email protected] [email protected].
We previously showed that guanine nucleotide-binding (G) protein α subunit (Gα)-interacting vesicle-associated protein (GIV), a guanine-nucleotide exchange factor (GEF), transactivates Gα activity-inhibiting polypeptide 1 (Gαi) proteins in response to growth factors, such as EGF, using a short C-terminal motif. Subsequent work demonstrated that GIV also binds Gαs and that inactive Gαs promotes maturation of endosomes and shuts down mitogenic MAPK-ERK1/2 signals from endosomes. However, the mechanism and consequences of dual coupling of GIV to two G proteins, Gαi and Gαs, remained unknown. Here we report that GIV is a bifunctional modulator of G proteins; it serves as a guanine nucleotide dissociation inhibitor (GDI) for Gαs using the same motif that allows it to serve as a GEF for Gαi. Upon EGF stimulation, GIV modulates Gαi and Gαs sequentially: first, a key phosphomodification favors the assembly of GIV-Gαi complexes and activates GIV's GEF function; then a second phosphomodification terminates GIV's GEF function, triggers the assembly of GIV-Gαs complexes, and activates GIV's GDI function. By comparing WT and GIV mutants, we demonstrate that GIV inhibits Gαs activity in cells responding to EGF. Consequently, the cAMP→PKA→cAMP response element-binding protein signaling axis is inhibited, the transit time of EGF receptor through early endosomes are accelerated, mitogenic MAPK-ERK1/2 signals are rapidly terminated, and proliferation is suppressed. These insights define a paradigm in G-protein signaling in which a pleiotropically acting modulator uses the same motif both to activate and to inhibit G proteins. Our findings also illuminate how such modulation of two opposing Gα proteins integrates downstream signals and cellular responses.